Literature DB >> 1687645

HIV-induced syncytium formation requires the formation of conjugates between virus-infected and uninfected T-cells in vitro.

M Busso1, J Thornthwaite, L Resnick.   

Abstract

The transmission of HIV requires the interaction of the cell-surface CD4 receptor and the viral envelope glycoprotein. Experiments were performed to determine the role of other cell-surface molecules in the development of HIV-induced syncytia. Although CEM and MT-2 cells had similar cell-surface CD4 receptor densities, less than 1% of CEM cells and greater than 95% of MT-2 cells formed syncytia with H9 cells chronically infected with HIV-1 (H9-IIIB). When compared with CEM cells, MT-2 cells exhibited a 10-fold and threefold greater capacity to form homotypic and heterotypic conjugates with H9 cells, respectively. Increasing the conjugate formation capacity of CEM cells with the lectin wheat germ agglutinin led to a greater than 30-fold increase in the formation of syncytia with H9/IIIB cells. The formation of syncytia between MT-2 and H9/IIIB cells was magnesium-, energy-, temperature-, and actin-cytoskeleton-dependent, and could be inhibited (65%) by an anti-LFA-1 monoclonal antibody. The combination of anti-leukocyte function-associated antigen-1 (LFA-1) and anti-CD2 monoclonal antibodies resulted in a synergistic inhibition (89%) of syncytium formation. These results indicate that integrins and other cell-surface adhesion molecules regulate HIV-induced syncytium formation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687645     DOI: 10.1097/00002030-199112000-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  Analysis of the murine leukemia virus R peptide: delineation of the molecular determinants which are important for its fusion inhibition activity.

Authors:  C Yang; R W Compans
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  The large subunit of HIV-1 reverse transcriptase interacts with beta-actin.

Authors:  M Hottiger; K Gramatikoff; O Georgiev; C Chaponnier; W Schaffner; U Hübscher
Journal:  Nucleic Acids Res       Date:  1995-03-11       Impact factor: 16.971

3.  Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1.

Authors:  M B Gomez; J E Hildreth
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

4.  Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis.

Authors:  W A Banks; E O Freed; K M Wolf; S M Robinson; M Franko; V B Kumar
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Analysis of the cell fusion activities of chimeric simian immunodeficiency virus-murine leukemia virus envelope proteins: inhibitory effects of the R peptide.

Authors:  C Yang; R W Compans
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  Investigation of the complement receptor 3 (CD11b/CD18) in human rectal epithelium.

Authors:  L A Hussain; C G Kelly; A Rodin; M Jourdan; T Lehner
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

7.  The phorbol ester phorbol myristate acetate inhibits human immunodeficiency virus type 1 envelope-mediated fusion by modulating an accessory component(s) in CD4-expressing cells.

Authors:  H Golding; J Manischewitz; L Vujcic; R Blumenthal; D S Dimitrov
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.

Authors:  N Sullivan; Y Sun; Q Sattentau; M Thali; D Wu; G Denisova; J Gershoni; J Robinson; J Moore; J Sodroski
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 9.  Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.

Authors:  Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.